HLA Associations in the Antitumor Response Against Malignant Melanoma

Journal of Immunotherapy

Volumn 18, Issue 4, 1995, Pages 242-252

  Marincola, Francesco M ^a   Shamamian, Peter ^a   Rivoltini, Licia ^a   Salgaller, Michael ^a   Cormier, Janice ^a   Restifo, Nicholas P ^a   Simonis, Toni B ^a   Venzon, David ^a   White, Donald E ^a   Parkinson, David R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

HLA; Malignant melanoma; NAC patients

Indexed keywords

INTERLEUKIN 2;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TOLERABILITY; HLA SYSTEM; HLA TYPING; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

GENE FREQUENCY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; MELANOMA; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029549950     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199511000-00005     Document Type: Article

References (52)

1. Lechler R. HLA and disease. London, Boston, New York: Academic Press, 1994.
2. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990;59:253-88.
3. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12.
4. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS,Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
5. Carreno BM, Koenig S, Coligan JE, Biddison WE. The peptide binding specificity of HLA class I molecules is largely allele-specific and non-overlapping. Mol Immunol 1992;29:1131-40.
6. Ryder LP, Andersen E, Svejgaard A. An HLA map of Europe. Hum Hered 1978;28:171-200.
7. Lee J, Reveille J, Ross M, Platsoucas C. HLA-DQB 1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994;59:510-3.
8. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
9. Pardoll DM: Tumour antigens. A new look for the 1990s [news; comment]. Nature 1994;369:357.
10. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
11. Brown JH, Jardetzky TS, Gorga JC, et al. Threedimensional structure of the human class II histocompatibility antigen HLA-DR1 [see comments]. Nature 1993;364:33-9.
12. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2- restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
13. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
14. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
15. Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994;39:105-16.
16. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN- gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-81.
17. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDe-vitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-7.
18. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993;23: 224-31.
19. Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988;8:426-36.
20. Blay JY, Favrot MC, Negrier S, et al. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990;50:2371-4.
21. Hopkins KA, van Leeuwen A, Tardiff GN, LeFor WM. Lymphotoxicity testing. In: Zachary AA, Teresi GA, eds. ASHI laboratory manual. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, 1990:195-9.
22. Imanishi T, Tatsuya A, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. Oxford, New York, Tokyo: Oxford Science Publications, 1994:1063-220.
23. Lee TD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In: Lee J, ed. The HLA system. New York: Springer-Verlag, 1990:141-78.
24. Marincola FM, Rosenberg SA. Biologic therapy with interleukin-2. Clinical applications-Melanoma. In: DeVita VT, Heilman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1995:250-62.
25. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report [see comments]. N Engl J Med 1988;319:1676-80.
26. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.
27. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994;43:18-27.
28. Mitchell MS, Harel W. Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 1992;10:1158-64.
29. Scheibenbogen C, Keiholz U, Manasterski M, Tilgen W, Hunstein W. MHC-molecules and immunotherapy of malignant melanoma. Melanoma Res 1993;3:77.
30. Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res 1994;4:191-4.
31. Rubin JT, Adams SD, Simonis T, Lotze MT. HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Proc Soc Biol Ther Annu Meet 1991;1:18.
32. Marincola FM, Balkissoon J, Schwartzentruber DJ, et al. Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. J Immunother 1993;13:282-8.
33. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992;148:638-43.
34. Lawlor DA, Ward FE, Ennis PD, Jackson AP, Parham P. HLA-A and B polymorphisms predate the divergence of humans and chimpanzees. Nature 1988;335:268-71.
35. Piazza A, Menozzi P, Cavalli-Sforza LL. The HLA-A,B gene frequencies in the world: migration or selection? Hum Immunol 1980;1:297-304.
36. Watkins DI, McAdam SN, Liu X, et al. New recombinant HLA-B alleles in a tribe of South American Amerindians indicate rapid evolution of MHC class I loci. Nature 1992;357:329-33.
37. Panza N, Del Vecchio L, Maio M, et al. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens 1982;20:155-8.
38. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3 [see comments]. Nature 1991;352:723-5.
39. Wank R, Schendel DJ, Thomssen C. HLA antigens and cervical carcinoma [letter; comment]. Nature 1992;356:22-3.
40. Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 1994;43:7-17.
41. Dawkins RL, Degli-Esposti MP, Abraham LJ, Zhang W, Christiansen FT. Conservation versus polymorphism of the MHC in relation to transplantation, immune responses and autoimmune disease. In: Klein J, Klein D, eds. Molecular evolution of the major histocompatibility complex. Berlin: Springer-Verlag, 1991:391-402.
42. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2- microglobulin messenger RNA. J Clin invest 1993;91:684-92.
43. D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991;87:284-92.
44. Marincola FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
45. Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O’Dea T, et al. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 1994;16:13-23.
46. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
47. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. The loss of functional β2- microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J Natl Cancer Inst 1996;88:100-8.
48. Hildebrand WH, Madrigal JA, Belich MP, et al. Serologic cross-reactivities poorly reflect allelic relationships in the HLA-B12 and HLA-B21 groups: dominant epitopes of the alpha 2 helix. J Immunol 1992;149:3563-8.
49. Parham P. Typing for class I HLA polymorphism: past, present, and future. Eur J Immunogen 1992;19:347-59.
50. Marincola FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appears in Cancer Res 1993;53:3846]. Cancer Res 1992;52:6561-6.
51. Jongeneel CV, Briant L, Udalova IA, Sevin A, Nedospasov SA, Cambon-Thomsen A. Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sci USA 1991;88:9717-21.
52. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL. Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 1986;83:8699-702.